Cowen Raises Price Target on Acadia Pharma (ACAD) Following 2Q15
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Acadia Pharmaceuticals (ACAD) PT Raised to $49 at Needham & Company Ahead of NDA Submission
August 7, 2015 8:36 AM EDTNeedham & Company analyst Alan Carr reiterated a Buy rating and boosted his price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $49.00 (from $38.00) following Q2 results and ahead of NDA submission.
Carr commented, "Acadia hosted a quarterly conference call last night. Mgmt guided for Nuplazid NDA... More
Piper Jaffray Downgrades Acadia Pharmaceuticals (ACAD) to Neutral
August 7, 2015 7:02 AM EDTPiper Jaffray downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Overweight to Neutral with a price target of $48.00 (from $39.00), saying with the Pima' NDA filed the next steps may be more challenging.
Analyst Charles Duncan commented, "ACADIA ended 2Q with $271M in cash,... More
Acadia Pharma (ACAD) Misses Q2 EPS by 6c
August 6, 2015 4:15 PM EDTAcadia Pharma (NASDAQ: ACAD) reported Q2 EPS of ($0.39), $0.06 worse than the analyst estimate of ($0.33).
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
... More